Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Dr Chris Bremer commences as Neurizon Chief Executive Officer Highlights:  Dr Chris Bremer has commenced as Chief Executive Officer, marking an important leadership transition as Neurizon advances NUZ-001 through late-stage clinical development in ALS/MND  Dr Bremer brings over 20 years of international pharmaceutical and biotechnology leadership experience spanning clinical development, portfolio strategy, commercialisation and business development  Dr Bremer will lead Neurizon through the ongoing Phase 2/3 HEALEY ALS Platform Trial, with Regimen I fully enrolled and topline results expected in late Q2 CY2027  Shareholders are invited to join Neurizon’s Leadership Roundtable webinar on 8 October at 4.00pm AEDT, featuring Dr Bremer and members of Neurizon’s Board and management (registration details below) 1 October 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon” or “the Company”), a late clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to confirm that Dr Chris Bremer, MD, PhD, MBA, has today commenced as Chief Executive Officer, and Mr Sergio Duchini has transitioned from Interim Executive Chairman to Non-Executive Chairman. Dr Bremer’s commencement marks an important leadership transition for Neurizon as the Company advances its lead investigational therapy, NUZ-001, through Regimen I of the registrational Phase 2/3 HEALEY ALS Platform Trial. Enrolment in Regimen I has been completed (refer ASX announcement: 17 July 2026), with 250 participants enrolled across 78 clinical sites in the United States. Topline results are expected in late Q2 CY2027. With the trial now progressing towards readout, Neurizon remains focused on disciplined clinical and regulatory execution while continuing to strengthen its organisational, manufacturing, partnering and commercial readiness for the potential pathways that may follow, subject to the clinical data. Upcoming webinar: Neurizon’s leadership roundtable – The road ahead To mark this next phase, Neurizon invites shareholders and investors to join a webinar on Thursday, 8 October 2026 at 4.00pm AEDT. The webinar will feature a roundtable discussion with Dr Bremer and members of Neurizon’s leadership team, exploring the Company’s recent progress, the advancement of NUZ-001 and Neurizon’s priorities. The discussion will be followed by a live Q&A, providing the opportunity to hear directly from the leadership team. Participants are encouraged to submit questions in advance via registration form or by emailing enquiries@neurizon.com.  Date: Thursday, 8 October 2026  Time: 4.00pm AEDT  Register: https://bit.ly/neurizonroundtable Leadership for Neurizon’s next phase Dr Bremer brings over 20 years of international pharmaceutical and biotechnology leadership experience spanning drug development, portfolio strategy, commercialisation and business development. His career includes approximately 20 years at Grünenthal, where he held a series of senior global executive roles including Executive Vice President, Early Products & Commercial Opportunities and Interim Chief Commercial Officer. Throughout his career, Dr Bremer has worked at the intersection of scientific development and commercial strategy, evaluating development-stage assets, shaping portfolio strategy and executing more than US$1 billion in licensing transactions. Dr Bremer’s experience across pharmaceutical development, commercial strategy and business development is closely aligned with Neurizon’s next phase as the Company progresses towards an important clinical data readout and prepares for the potential regulatory, partnering and commercial pathways that may follow. Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Management commentary Chief Executive Officer, Dr Chris Bremer said: “I am delighted to formally commence as CEO of Neurizon at an important point in the Company’s development. Neurizon has established a strong foundation around NUZ-001, with an advanced clinical program and an international network spanning clinical development, regulatory, manufacturing and scientific capabilities. “My immediate priority is disciplined execution as Regimen I progresses towards topline results. At the same time, we need to ensure that Neurizon is prepared to respond to the potential regulatory, development and strategic pathways that may emerge from the data. “Having spent much of my career connecting scientific and clinical development with portfolio strategy, commercialisation and strategic partnerships, I see significant value in bringing those disciplines together as Neurizon enters this next phase. “I look forward to working with the Neurizon team and the Board, and engaging with our clinical collaborators, partners, shareholders and the ALS/MND community as we continue to advance NUZ-001.” Non-Executive Chairman, Sergio Duchini, said: “On behalf of the Board, I am delighted to formally welcome Chris as Chief Executive Officer. Chris takes the leadership of Neurizon at an important stage, with enrolment in Regimen I complete, NIH-funded Expanded Access Program established, and the Company fully funded through the HEALEY readout and completion of the study. Our focus is now on maintaining disciplined execution while ensuring Neurizon is strategically prepared for the opportunities that may follow. “Over the past several months, the Neurizon team has delivered a number of important clinical, funding and corporate milestones. I am incredibly proud of what the team has achieved and grateful for their commitment during my time as Interim Executive Chairman. “Chris brings a highly complementary combination of scientific, commercial and transactional experience, and I look forward to working closely with him as Chairman to ensure a smooth transition and maintain the momentum the Company has built.” -ENDS- This announcement has been authorised for release by Sergio Duchini, Interim Executive Chairman, on behalf of the Board of Neurizon Therapeutics Limited. For further information, please contact: Marketing & Corporate Affairs Lidija Damjanovic Email: lidija@neurizon.com Phone: +61 (0) 425 700 504 Investor Relations Henry Jordan Email: henry.jordan@sdir.com.au Phone: +61 (0) 431 271 538 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical program, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction. Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Neurizon Investor Hub We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited